he 2012 Australian National Vascular Disease Prevention Alliance cardiovascular disease primary prevention guidelines 1 differ markedly from overseas guidelines in several respects. The American College of Cardiology/ American Heart Association (ACC/AHA) guidelines 2 assess risk with the pooled cohort equation (PCE), predicting hard cardiovascular outcomes only (death, myocardial infarction, stroke, resuscitated cardiac arrest), and may be less prone to overestimating risk than the Australian absolute cardiovascular disease risk (ACVDR) tool. Second, the current threshold for initiating statin therapy in Australia is ACVDR 5-year CVD risk of 10%; 1 the ACC/AHA guidelines recommend statin therapy for people with 10-year PCE risk of 7.5%. 2 Finally, the ACC/ AHA guidelines, but not the Australian guidelines, recognise the value of coronary artery calcium (CAC) scores for guiding treatment of people at intermediate risk of cardiovascular events. 1,2 CAC scores are correlated with atherosclerotic plaque burden and risk of cardiovascular disease (CVD) and, together with standard risk factors, can improve risk stratification; a consensus is emerging that statin therapy is warranted for people with CAC scores of 100 or more. 3,4 Moreover, by identifying subclinical disease and the potential benefit of reducing low density lipoprotein cholesterol (LDL-C) levels, CAC scoring may motivate clinicians to initiate and patients to adhere to statin therapy. 5,6 Recent position statements by the Cardiac Society of Australia and New Zealand (CSANZ) 7 and the National Heart Foundation (NHF) 8 reflect CAC recommendations in overseas guidelines, but note that local information on outcomes and cost-effectiveness is limited. A United States study found that statin treatment guided by CAC scores may be more cost-effective than standard predicted risk thresholds, and that adherence to therapy is an important contributor to its benefit. 9 We therefore evaluated the cost-effectiveness of CAC-guided and risk score-based statin treatment thresholds by analysing treatment outcomes for Australians with family histories of premature coronary artery disease.
MethodsWe analysed data from the Coronary Artery calcium score: Use to Guide management of HerediTary Coronary Artery Disease (CAUGHT-CAD) trial 10 (Australian New Zealand Clinical Trials Registry ACTRN12614001294640). This randomised controlled trial assessed the utility of CAC scoring for guiding